Having decades of experience at various companies, ClinDatrix staff bring great expertise in conducting clinical trials across all phases (I-III). We’ve completed studies in a diverse spectrum of cancers, including highly complex cases such as KRAS-mutant metastatic colorectal cancer, glioblastoma, and advanced pancreatic adenocarcinoma. Our team has successfully designed electronic data capture (EDC) databases for complex protocols for recurrent grade IV gliomas, metastatic melanoma, non-small cell lung cancer with KRAS or EGFR-activated tumors, bone and soft tissue sarcomas, and other aggressive cancers. Extensive experience in electronic case report form design, protocol refinement, clinical trial logistics and management positions ClinDatrix as a leader in clinical trials in oncology.
Key highlights of ClinDatrix oncology expertise:
- Agility in study management: Study database launch capabilities on our own servers within 5 weeks, versus the industry standard of 12, and protocol adjustments within 1-2 days, not weeks.
- Experienced team: ClinDatrix’s oncology teams average 20 years in the field, ensuring high-level execution and strategic guidance across all phases.
- Regulatory expertise: Proven ability to comply with industry standards and regulatory requirements.
ClinDatrix comprehensive support ensures that sponsors meet their study objectives precisely, backed by operational excellence and scientific rigor.
Contact ClinDatrix today to learn more about how our oncology study services can elevate your research projects.
ClinDatrix Oncology Studies:
Service Codes
- BI = Biostatistics
- CL = Clinical
- DM = Data Management
- FS = Full Service
- MS = Medical Safety
- MW = Medical Writing
- RA = Regulatory Affairs
| Phase | Indication | Services | Number of Sites | Number of Patients |
|---|---|---|---|---|
| 1 | Metastatic Cancer | FS | 1 | 21 |
| 1 | KRAS Mutant Metastatic Colorectal Cancer | BI, DM | 3 | 25 |
| 1 | KRAS Mutant Metastatic Colorectal Cancer | BI, DM | 3 | 36 |
| 1 | Advanced Solid Tumors | DM | 3 | 27 |
| 1 | Chronic Lymphocytic Leukemia | BI, DM | 5 | 10 |
| 1 | Extensive, recurrent, or metastatic sarcoma, melanoma, or carcinoma | CL, RA | 20 | 96 |
| 2 | Glioblastoma and Gliosarcoma | DM, CL | 1 | 25 |
| 2 | Advanced Pancreatic Adenocarcinoma | DM | 2 | 34 |
| 2 | Metastatic Melanoma | DM | 1 | 14 |
| 2 | Squamous Cell Carcinoma of the Lung | DM | 12 | 32 |
| 3 | Squamous Cell Carcinoma of the Head and Neck | BI, CL, DM, MW | 58 | 184 |
| 1/2A | Recurrent Grade IV Glioma | FS | 9 | 49 |
| 1B | Malignant Pleural Mesothelioma | BI, CL, DM | 5 | 60 |
| 1 | Solid Tumors | BI, DM | 5 | 27 |
| 1 | Advanced Solid Tumors or Lymphoma | BI, DM | 3 | 107 |
| 1 | Lymphocytic Leukemia | BI, DM | 1 | 8 |
| 1 | Lymphocytic Leukemia | BI, DM | 1 | 12 |
| 1 | Lymphocytic Leukemia | BI, DM | 1 | 2 |
| 1 | Metastatic Solid Tumors | BI, DM | 1 | 18 |
| 1 | Advanced Malignancies | BI, DM | 2 | 17 |
| 1 | Advanced Malignancies | BI, DM | 3 | 25 |
| 1 | Advanced Malignancies | BI, DM | 3 | 38 |
| 1 | Oncology | BI, CL, DM | 1 | 5 |
| 1 | Chronic Lymphocytic Leukemia | BI, DM | 3 | 15 |
| 1/2 | Malignant Gliomas | BI, DM | 3 | 18 |
| 1/2 | Advanced Malignancies | BI, DM | 2 | 34 |
| 1/2 | Oncology | BI | 4 | 20 |
| 1/2A | Basal Cell Carcinoma | FS | 3 | 27 |
| 1A/1B | Advanced Metastatic Solid Tumors and NSCLC | BI, DM, MS, MW | 7 | 84 |
| 1A/1B | Recurrent Head and Neck Cancer | BI, CL, DM, MS, MW | 7 | 40 |
| 2 | Advanced Cancers, including Head, Neck, and Esophageal Cancers | BI, DM | 3 | 16 |
| 2 | Bone and Soft Tissue Sarcomas Metastatic to the Lung | BI, DM | 4 | 53 |
| 2 | Squamous Cell Carcinoma of the Head and Neck | BI, DM | 2 | 14 |
| 2 | Non-Small Cell Lung Cancer accompanied by KRAS or EGFR Activated Tumors | BI, DM | 2 | 37 |
| N/A | Oncology | BI, DM | 1 | 19 |
| N/A | Oncology | BI, DM | 2 | 33 |
| N/A | Oncology | BI, DM | 2 | 25 |
| N/A | Oncology | BI, DM | 1 | 6 |
| N/A | Oncology | BI, DM | 1 | 12 |
| TBD | Prostate Cancer | CL | 1 | 167 |